The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.
Surgery at high-volume centers is associated with decreased local recurrence risk and improved survival for women with early-stage cervical cancer.
Mirvetuximab soravtansine is the first folate receptor alpha-targeting antibody-drug conjugate.
A new study challenges the recommended use of cotesting for cervical cancer screening.
When paired with bevacizumab, neither intraperitoneal delivery of carboplatin nor cisplatin improved outcomes for patients with advanced ovarian carcinoma compared with intravenous delivery.
The number of cervical precancers (CIN2+ cases) in the United States declined from 2008 to 2016.
More accurate biomarkers are needed to better define subgroups of patients with ovarian cancer who are most likely to benefit from late-line niraparib.
Pathogenic variants ID’d in 7.8 percent of patients with breast cancer, 14.5 percent with ovarian cancer
Coadministration of the HPV16-specific vaccine, ISA101, with chemotherapy was found to be associated with stronger tumor immunity.
Median OS was significantly improved when dendritic cell vaccination therapy was added to standard second-line chemo in platinum-sensitive, relapsed ovarian cancer.
Concurrent surgery for cancer and stress urinary incontinence was associated with significantly improved QoL for women with early endometrial neoplasms and urinary stress incontinence.
According to researchers, responses to TSR-042 were seen in subgroups of patients with disease characterized as microsatellite instability (MSI)-high and MSI-low.
Median PFS was only 2.9 months for women with advanced cervical cancer receiving the combination of atezolizumab plus bevacizumab.
A clinical benefit rate of 86% was observed in a phase 2 trial of pembrolizumab plus chemotherapy in patients with recurrent, platinum-resistant ovarian cancer.
According to researchers, responses to tisotumab vedotin were seen in women with refractory advanced cervical cancer.
High expression of indoleamine 2.3-dioxygenase pathway genes correlated with the presence of immune escape mechanisms in ovarian cancers, according to researchers.
Single-agent neratinib was associated with durable responses in a subcohort of women in the SUMMIT trial.
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
The OS benefit of carboplatin desensitization was limited to the subgroup of women with recurrent ovarian cancer without deleterious germline BRCA1/2 mutations.
Researchers estimated cost effectiveness for first-line maintenance therapy with bevacizumab or olaparib in women with BRCA-mutant ovarian cancer.